Is NCT07710196 recruiting in Dallas, TX?

Yes, NCT07710196 is currently recruiting participants at its Dallas, TX location. This retinitis pigmentosa (rp) clinical trial is actively enrolling qualified participants.

How do I join the retinitis pigmentosa (rp) clinical trial in Dallas?

To join this clinical trial in Dallas, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Dallas clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Retinitis Pigmentosa (RP) Clinical Trial in Dallas, TX

About This Retinitis Pigmentosa (RP) Study in Dallas

The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are: Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision. Participants will: Take NPI-001 or a placebo twice a day, every day for 24 months and visit the clinic 9 times for checkups and tests.

Sponsor: Nacuity Pharmaceuticals, Inc.

Who Can Participate

Inclusion Criteria

Able to comprehend and willing to sign an informed consent form (OCF) and adhere to the study protocol.

Diagnosed with RP associated with Usher syndrome.

EZ width ≥ 500 microns, which includes the fovea in each eye at Visit 1.

All edges of the EZ area in both eyes can be visualized at Visit 1 (Screening).

Have at least 20 detectable points on the MAIA grid in at least one eye at the Screening and Baseline visits (same eye for both visits).

On stable dose of medications associated with other conditions for at least one month.

Willing to use contraception during study (for anyone of childbearing potential).

Exclusion Criteria

Concurrent retinal pathologies that result in vision loss or inability to fixate.

Intraocular surgery within the last two months or capsulotomy within the last month.

Current or history of uveitis, Coat's disease, diabetic retinopathy, glaucoma, herpes simplex of the eye, or currently has a cataract that prevents visualization of the posterior pole.

Likely to require cataract surgery within the next 12 months.

Unstable fixation during microperimetry in either eye at either Screening or Baseline visits.

Use of any other investigational new drug, or participation in another clinical trial within 12 weeks before the start of study treatment.

Use of N-acetylcysteine containing products in the previous 30 days prior to the baseline visit or unwilling to refrain from such supplements for the duration of the study.

Chronic liver or kidney disease, cystic fibrosis, severe asthma, or chronic obstructive pulmonary disease (COPD), history of thrombocytopenia not due to a reversible cause, or other blood dyscrasia.

Suspected liver dysfunction determined by having alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin values \> 1.5 X the upper limit of normal (ULN) at screening.

Platelet or hemoglobin values \< 100 at screening.

History of known sensitivity to N-acetylcysteine or similar thiol compounds or any ingredients of NPI-001.

History of hypersensitivity to any medication or food resulting in systemic symptoms.

History of cancer (other than non-melanoma skin cancer) diagnosed or requiring treatment within the past 2 years.

Pregnant women or women planning to become pregnant in the next 25 months or men with partners planning to become pregnant in the next 25 months.

Lactating women who are breast-feeding.

Potential participant lives in the same household as a current participant in this study.

Subjects who are unwilling or unable to refrain from donation of blood from 30 days prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening until 56 days following the last study drug dose administered.

Inability to provide blood samples, including difficulty with venous access.

Any reason, in the opinion of the Principal Investigator, the participant should not participate.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Dallas?

Yes, this clinical trial (NCT07710196) has an active research site in Dallas, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Retinitis Pigmentosa (RP) Treatment Options in Dallas, TX

If you're searching for retinitis pigmentosa (rp) treatment options in Dallas, TX, this clinical trial (NCT07710196) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Dallas research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced retinitis pigmentosa (rp) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all retinitis pigmentosa (rp) clinical trials near you to find additional studies recruiting in your area.

Retinitis Pigmentosa (RP) Clinical Trial in Dallas, TX

Expert Care in Dallas

IRB Approved

No-Cost Care

Apply for This Dallas Location

Why Participate?

Simple Process